中新网四川新闻1月19日电 题：简阳这五年：从"规划蓝图"到"落笔生花" 作者 吴平华 曹礼芹 五载耕耘，秋收其实，奋进中的简阳坚持把深入推进城乡融合高质量发展作为谋划一切工作的逻辑起 点，进一步强基础、扬优势、提能级，全力以赴推动高质量发展，争做县域经济排头兵，将"十四五"规 划蓝图变为身边风景。 机场。简阳市融媒体中心供图 在发展能级上，全国百强县连续5年实现进位、上升至第79位，成为四川省"首位县"；在发展格局上， 被赋予"国际空港门户枢纽城市、成渝发展主轴重要节点、四川省丘区乡村振兴示范"功能定位，肩负建 设成都市域副中心的重大使命；在发展方式上，创新驱动、绿色崛起、开放带动发展动能加速集聚，发 展韧性与活力显著增强；在发展品质上，"天府门户、空港简阳"城市品牌形象愈发鲜明，城市辨识度与 美誉度持续提升，现代化简阳实践迈出新的坚实步伐。 天府国际 简阳城市 候机楼。简阳市融媒体中心供图 四川港通医疗设备集团股份有限公司供气产品车间内，在"一丝不苟"的品控下，该公司生产的产品备受 市场的推崇，医用气体系统领域全国市场占有率第一。作为简阳市低温装备产业集群的链主企业，该公 司还深度参与制定了今年7月1日实 ...

"十四五"以来，简阳坚定"工业立市、制造强市"鲜明导向，以科技创新为引擎，以产业升级为抓手，推动传统产 业焕新发展、新兴产业加速崛起，全市制造业整体迈上新台阶，为简阳加快建成全国百强千亿县、全力打造成都 市域副中心注入强劲动能。 特色产业集群加快构建 规上工业增加值增速位列成都区县NO.1 低温装备产业集群挺起工业"立柱"，绿色食品产业同步"架梁"。四川省新欣火娃食品有限公司自动化产线全速运 转，三只松鼠西南供应链集约生产基地物流繁忙，分装产线高效生产……"园区依托海底捞等餐饮龙头，做强颐 海、火娃等火锅底料供应能力，打造川味火锅品牌，依托三只松鼠产业链整合能力，拓展产销服务。"简阳经开区 产业发展部负责人介绍，全市已汇聚颐海食品、嘉美食品、三只松鼠等多家重点企业，形成复合调味品、饮料灌 装、配套设备等产业聚集，正加快打造火锅底料和休闲食品特色产业园。 特色产业集群崛起，加速勾勒简阳产业发展新版图。"十四五"期间，简阳推出涵盖产业、科技、人才的工业领域 政策"组合拳"，推动主导产业从机械零部件加工、能源化工、食品加工加快转向以新能源与智能网联汽车为首位 产业，提质发展智能装备制造、人工智能、绿色食品三大优势产 ...

诺安多策略混合A（320016）基金经理为孔宪政。 截至发稿，孔宪政累计任职时间5年49天，现任基金资产总规模56.08亿元，任职期间最佳基金回报 93.39%， 任职期间最差基金回报-16.74%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月13日，港通医疗涨5.04%，截至发稿，报26.49元/股，成交1.54亿元，换手率9.51%，总市值26.49亿 元。 资料显示，四川港通医疗设备集团股份有限公司位于四川省成都市简阳市凯力威工业大道南段356号， 成立日期1998年1月13日，上市日期2023年7月25日，公司主营业务涉及为医疗机构提供以医用气体系统 及医院洁净手术部为核心的医疗专业工程整体方案。主营业务收入构成为：医用洁净装备及系统 55.69%，医用气体装备及系统37.30%，医疗设备及其他产品销售4.06%，运维服务2.81%，其他(补 充)0.14%。 从港通医疗十大流通股东角度 数据显示，诺安基金旗下1只基金位居港通医疗十大流通股东。诺安多策略 ...

Group 1 - The core point of the news is that 港通医疗 experienced a decline of 5.02% in its stock price, reaching 24.20 yuan per share, with a trading volume of 205 million yuan and a turnover rate of 13.05%, resulting in a total market capitalization of 2.42 billion yuan [1] - 港通医疗, established on January 13, 1998, and listed on July 25, 2023, specializes in providing medical gas systems and clean surgical room solutions to healthcare institutions [1] - The revenue composition of 港通医疗 includes: 55.69% from clean medical equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from sales of medical devices and other products, 2.81% from operation and maintenance services, and 0.14% from other sources [1] Group 2 - 诺安多策略混合A (320016) is among the top ten circulating shareholders of 港通医疗, holding 725,100 shares, which accounts for 1.15% of the circulating shares, with an estimated floating loss of approximately 928,100 yuan [2] - 诺安多策略混合A was established on August 9, 2011, with a latest scale of 1.855 billion yuan, achieving a year-to-date return of 2.79% and a one-year return of 80.52% [2] - The fund manager of 诺安多策略混合A is 孔宪政, who has been in the position for 5 years and 45 days, with the fund's total asset scale at 5.608 billion yuan, achieving a best return of 86.44% and a worst return of -16.74% during his tenure [3]

Group 1 - The core viewpoint of the news is that Kangtong Medical has shown significant stock performance with a 14.16% increase on January 5, 2023, and a trading volume of 218 million yuan [1] - As of January 5, 2023, Kangtong Medical's financing balance reached 42.45 million yuan, accounting for 2.66% of its market capitalization, indicating a high level of financing activity compared to the past year [1] - The company primarily engages in providing medical gas systems and clean operating room solutions, with its main revenue sources being clean equipment and systems (55.69%) and medical gas equipment and systems (37.30%) [1] Group 2 - As of December 31, 2022, the number of shareholders for Kangtong Medical was 7,415, a decrease of 1.64% from the previous period, while the average circulating shares per person increased by 1.67% to 8,501 shares [2] - For the period from January to September 2025, Kangtong Medical reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% [2] - Since its A-share listing, Kangtong Medical has distributed a total of 48.997 million yuan in dividends [3]

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) has shown a mixed performance in terms of financing and stockholder metrics, with a notable decrease in revenue and profit in recent periods [1][2]. Group 2 - As of December 31, 港通医疗's stock price increased by 0.30%, with a trading volume of 18.21 million yuan [1]. - The financing data indicates that on the same day, 港通医疗 had a financing buy amount of 1.00 million yuan and a financing repayment of 1.77 million yuan, resulting in a net financing buy of -0.77 million yuan [1]. - The total financing and margin trading balance for 港通医疗 reached 28.46 million yuan, which is 2.03% of its circulating market value, indicating a low financing balance compared to the past year [1]. Group 3 - 港通医疗's main business involves providing medical institutions with overall solutions centered on medical gas systems and clean operating rooms, with revenue contributions of 55.69% from clean equipment and systems, 37.30% from medical gas equipment and systems, and 4.06% from other medical equipment sales [1]. - As of December 19, the number of shareholders for 港通医疗 increased to 7,539, while the average circulating shares per person decreased to 8,362 shares [2]. - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to the parent company of -10.21 million yuan, a year-on-year decrease of 150.92% [2]. Group 4 - 港通医疗 has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]. - As of September 30, 2025, the top ten circulating shareholders included 诺安多策略混合A (Noah Multi-Strategy Mixed A), which holds 725,100 shares as a new shareholder [3].

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) is experiencing a decline in stock performance and financial metrics, with significant decreases in revenue and net profit reported for the year [1][2] - As of December 26, 港通医疗's stock price fell by 1.17%, with a trading volume of 17.42 million yuan, and a net financing purchase of 126,600 yuan [1] - The company's financing balance is 29.31 million yuan, accounting for 2.08% of its market capitalization, which is below the 10th percentile level over the past year, indicating a low financing level [1] Group 2 - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the number of shareholders for 港通医疗 increased by 2.5% to 7,539, while the average circulating shares per person decreased by 2.44% to 8,362 shares [2][3]

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) is experiencing a decline in stock performance and financial metrics, with significant decreases in revenue and net profit reported for the year 2025 [1][2] - As of December 17, 港通医疗's stock price fell by 0.71%, with a trading volume of 16.32 million yuan, and a net financing buy of -1.29 million yuan, indicating a negative sentiment among investors [1] - The financing balance of 港通医疗 is 27.04 million yuan, which accounts for 1.98% of its market capitalization, indicating a low level of financing compared to the past year [1] Group 2 - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a significant decline of 150.92% [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the number of shareholders for 港通医疗 is 7,355, a decrease of 1.68%, while the average circulating shares per person increased by 1.71% to 8,571 shares [2]

Group 1 - The core viewpoint of the news is that Kangtong Medical has shown a decrease in financing activities and a significant drop in revenue and net profit for the year 2025 [1][2] - As of December 15, Kangtong Medical's financing balance is 28.75 million yuan, accounting for 2.07% of its market capitalization, which is below the 10th percentile level over the past year, indicating a low financing level [1] - The company reported a revenue of 344 million yuan for the period from January to September 2025, representing a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% year-on-year [2] Group 2 - Kangtong Medical's main business includes providing medical gas systems and clean operating room solutions, with revenue composition being 55.69% from clean equipment and systems, 37.30% from medical gas equipment, and 4.06% from other medical device sales [1] - As of December 10, the number of shareholders for Kangtong Medical is 7,355, a decrease of 1.68% from the previous period, while the average circulating shares per person increased by 1.71% to 8,571 shares [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) is experiencing a decline in stock performance and financial metrics, with a notable drop in revenue and net profit [1][2] - On December 10, 港通医疗's stock fell by 2.09%, with a trading volume of 19.84 million yuan, and a net financing purchase of 397,600 yuan [1] - The company's financing balance is 29.25 million yuan, accounting for 2.00% of its market capitalization, which is below the 10th percentile level over the past year, indicating a low financing level [1] Group 2 - As of November 28, the number of shareholders for 港通医疗 decreased by 5.24% to 7,481, while the average circulating shares per person increased by 5.53% to 8,426 shares [2] - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% [2] - 港通医疗 has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]